The global biodefense market offers various biodefense products that help defend against potential biological threats and diseases. Biodefense products include vaccines, recombinant proteins & antibodies, and small molecule inhibitors that are used for detection, protection and treatment against biological threats. Rising instances of pandemics have increased the demand for vaccines and other biodefense products that are effective in countering biological threats.
The global biodefense market is estimated to be valued at US$ 13.04 Bn in 2023 and is expected to exhibit a CAGR of 7.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising demand for effective biodefense products is one of the key trends driving the growth of the biodefense market. Frequent outbreaks of infectious diseases like COVID-19, Ebola, and Zika have heightened awareness about the need for reliable biodefense products among governments and healthcare organizations. This has prompted increased investments in R&D activities focused on developing novel and innovative biodefense solutions. Many companies in the market are engaged in developing advanced vaccines, drugs, and diagnostic kits to detect and limit the spread of potential biological threats at a faster pace. The growing adoption of proactive measures for combating pandemics is expected to boost the demand for biodefense products, thereby propelling the market growth over the forecast period.
Segment Analysis
The Global Biodefense Market Size is dominated by medical countermeasures sub segment. This is because various government organizations such as National Institute of Allergy and Infectious Diseases etc. have been heavily investing in medical countermeasures such as vaccines to fight against biological threats. Currently, anthrax vaccine leads the medical countermeasures sub segment.
Key Takeaways
The North America region currently dominates the biodefense market with over 35% share driven by increasing bioterrorism threat perception and heavy investments in preparedness programs.
Regional analysis: The Asia Pacific biodefense market is projected to grow at highest CAGR during the forecast period. Countries such as India, China and South Korea are increasing their spending on biodefense preparedness programs to strengthen their capabilities against potential biological threats. For example, in 2022, Indian government announced providing additional funding of over US$ 600 Mn to accelerate development of vaccines and therapeutics against high threat pathogens.
Key players operating in the biodefense market are ADM, PT Darya-Varia Laboratoria Tbk, Citra Nusa Insan Cemerlang PT, Sido Muncul PT, The Tempo Group, Bayer AG, BASF SE, Pfizer Inc., Nature€TMs Sunshine Products, Inc., Amway, and Glanbia PLC. Major players are focusing on strengthening their medical countermeasures portfolio through acquisitions and partnerships. For instance, in 2021, Pfizer acquired certain developmental programs from ReViral for respiratory syncytial virus vaccine candidate.
Get more insights on this topic:
Global Biodefense market is valued at USD 5.31 Billion in 2018 and expected to reach USD 7.22 Billion by 2025 with the CAGR of 4.5 %over the forecast period.Favorable government initiatives, Increase in the number of naturally occurring outbreaks, and increasing threat of biological weapons and nuclear armed ICBM are some of the major factors driving the growth of global biodefense marketBiodefense constitutes the use of medical measures to protect individuals against bioterrorism including interventions such as drugs and vaccinations but also research and public health preparations to defend against such biological attack.
The goal of biodefense is to integrate the sustained efforts of the national and homeland security, medical, public health, intelligence, diplomatic, and law enforcement communities.
Biodefense is an emerging industry that offers new opportunities for both existing and new drug companies, as well as for biotechnology companies with technologies for drug discovery and pathogen detection.Get Sample Copy of This Premium Report: @ https://industrystatsreport.com/Request/Sample?ResearchPostId=12902=SampleGlobal biodefense market report is segmented on the basis of product type, application and regional& country level.
On the basis of country level, market of Biodefense is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.Biodefense CompaniesElusys Therapeutics, Inc.Emergent BioSolutions, Inc.DynPort Vaccine Company, LLCSIGA TechnologiesPharmAthene, Inc.Cleveland BioLabsIchor Medical SystemsAchaogen, Inc.Xoma CorporationDynavax Technologies CorporationBavarian Nordic others.Favorable government initiatives, increase in the number of naturally occurring outbreaks, and increasing threat of biological weapons and nuclear armed ICBM are some of the major factors driving the growth of global biodefense market.Favorable government initiatives, increase in the number of naturally occurring outbreaks, and increasing threat of biological weapons and nuclear armed ICBM are some of the major factors driving the growth of global biodefense market.
For instance, Centers for Disease Control and Prevention estimates, between 2016 and 2017, nearly 30 Million people suffered from influenza in the country.
For instance, according to the World Health Organization, More than 28,000 people were infected, and over 11,000 people died before the international public health emergency ended in June 2016.
